{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:54:41Z","timestamp":1790132081000,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0019\/2022\/AGJ"],"award-info":[{"award-number":["0019\/2022\/AGJ"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0001\/2023\/AKP"],"award-info":[{"award-number":["0001\/2023\/AKP"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["006\/2023\/SKL"],"award-info":[{"award-number":["006\/2023\/SKL"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116423","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:03:20Z","timestamp":1771970600000},"page":"116423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oridonin downregulates PD-L1 expression and promotes anti-tumor immunity via inhibiting NLRP3 and STAT3"],"prefix":"10.1016","volume":"175","author":[{"given":"Meng-Yu","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can-Can","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Ming","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116423_bb0005","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.15442","article-title":"Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis","volume":"113","author":"Saito","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2026.116423_bb0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-024-02059-y","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116423_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116423_bb0020","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116423_bb0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116423_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104588","article-title":"Innovations in cancer immunotherapy: a comprehensive overview of recent breakthroughs and future directions","volume":"206","author":"Hsu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2026.116423_bb0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12935-021-01946-4","article-title":"Small molecule inhibitors against PD-1\/PD-L1 immune checkpoints and current methodologies for their development: a review","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2026.116423_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116267","article-title":"Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents","volume":"268","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116423_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2026.116423_bb0050","article-title":"Network medicine-based strategy identifies Maprotiline as a Repurposable drug by inhibiting PD-L1 expression via targeting SPOP in Cancer","volume":"12","author":"Tian","year":"2025","journal-title":"Adv Sci (Weinh)."},{"key":"10.1016\/j.intimp.2026.116423_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 expression by NF-kappaB in Cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116423_bb0060","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1002\/jcp.29671","article-title":"Role of tumor microenvironment in the regulation of PD-L1: a novel role in resistance to cancer immunotherapy","volume":"235","author":"Kalantari Khandani","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2026.116423_bb0065","doi-asserted-by":"crossref","first-page":"20683","DOI":"10.1074\/jbc.M117.809053","article-title":"MicroRNA-155 induction via TNF-alpha and IFN-gamma suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells","volume":"292","author":"Yee","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2026.116423_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108512","article-title":"NLRP3 promotes immune escape by regulating immune checkpoints: a pan-cancer analysis","volume":"104","author":"Ding","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116423_bb0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2020.10.024","article-title":"NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma","volume":"497","author":"Lu","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116423_bb0080","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/ITT.S495564","article-title":"NLRP3 Inflammasome upregulates PD-L1 in ovarian Cancer and contributes to an immunosuppressive microenvironment","volume":"13","author":"Pan","year":"2024","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.intimp.2026.116423_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad346","article-title":"COIMMR: a computational framework to reveal the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming","volume":"24","author":"Tian","year":"2023","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.intimp.2026.116423_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155497","article-title":"Arenobufagin enhances T-cell anti-tumor immunity in colorectal cancer by modulating HSP90beta accessibility","volume":"128","author":"Shang","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2026.116423_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155898","article-title":"Curcumin enhances anti-tumor immunity in anaplastic thyroid carcinoma by elevating CD8+ T cell function and downregulating the AKT\/mTORC1\/STAT3\/PD-L1 axis","volume":"269","author":"Zheng","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.intimp.2026.116423_bb0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.canlet.2008.05.025","article-title":"Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells","volume":"270","author":"Liang","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116423_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110669","article-title":"Oridonin enhances cytotoxic activity of natural killer cells against lung cancer","volume":"122","author":"Hwang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116423_bb0110","doi-asserted-by":"crossref","first-page":"23878","DOI":"10.18632\/oncotarget.24378","article-title":"Oridonin inhibits aberrant AKT activation in breast cancer","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.116423_bb0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-023-02702-4","article-title":"Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer","volume":"42","author":"Zhou","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116423_bb0120","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/jcmm.17841","article-title":"Oridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha\/androgen receptor\/TGF-beta signalling pathway axis","volume":"27","author":"Gao","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116423_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1606325","article-title":"Research progress and molecular mechanism of oridonin in the treatment of malignant melanoma","volume":"15","author":"Deng","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116423_bb0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12032-014-0365-1","article-title":"Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells","volume":"32","author":"Li","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2026.116423_bb0135","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3892\/ijo.2016.3488","article-title":"Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR\/ERK\/MMP-12 and CIP2A\/Akt signaling pathways","volume":"48","author":"Xiao","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2026.116423_bb0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1471-2407-14-217","article-title":"Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway","volume":"14","author":"Bao","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.116423_bb0145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7150\/ijms.70733","article-title":"Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2\/STAT3 signaling","volume":"19","author":"Liu","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.intimp.2026.116423_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155426","article-title":"Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1","volume":"126","author":"Liu","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2026.116423_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176656","article-title":"Oridonin, a small molecule inhibitor of cancer stem cell with potent cytotoxicity and differentiation potential","volume":"975","author":"Li","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116423_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad027","article-title":"Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM","volume":"24","author":"Tian","year":"2023","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.intimp.2026.116423_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.apsb.2024.08.017","article-title":"GSFM: a genome-scale functional module transformation to represent drug efficacy for in silico drug discovery","volume":"15","author":"Tian","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2026.116423_bb0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11805-007-0016-9","article-title":"The inhibitory effect of oridonin on the growth of fifteen human cancer cell lines","volume":"4","author":"Chen","year":"2007","journal-title":"Chin. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116423_bb0175","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116423_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/BS9.0000000000000149","article-title":"PD-L1: expression regulation","volume":"5","author":"Zhou","year":"2023","journal-title":"Blood Sci."},{"key":"10.1016\/j.intimp.2026.116423_bb0185","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejphar.2017.09.021","article-title":"Oridonin induces G2\/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma","volume":"815","author":"Wang","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116423_bb0190","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/carcin\/bgad072","article-title":"Interplay between inflammasomes and PD-1\/PD-L1 and their implications in cancer immunotherapy","volume":"44","author":"Jiao","year":"2023","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.intimp.2026.116423_bb0195","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1189\/jlb.5RU0714-360RR","article-title":"Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP","volume":"97","author":"Fabbi","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2026.116423_bb0200","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1002\/mco2.447","article-title":"NLRP3\/IL-1beta induced myeloid-derived suppressor cells recruitment and PD-L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.intimp.2026.116423_bb0205","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3389\/fimmu.2019.01337","article-title":"Recent findings in the regulation of programmed death ligand 1 expression","volume":"10","author":"Shen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116423_bb0210","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1002\/jcp.29750","article-title":"STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses","volume":"235","author":"Jahangiri","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2026.116423_bb0215","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12032-025-02666-9","article-title":"Isoliquiritigenin attenuates tumor progression and PD-L1 expression by inhibiting the phosphorylation of STAT3 in melanoma","volume":"42","author":"Zeng","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2026.116423_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175856","article-title":"Oridonin inhibits the occurrence and development of colorectal cancer by reversing the Warburg effect via reducing PKM2 dimer formation and preventing its entry into the nucleus","volume":"954","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116423_bb0225","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/ijms.48552","article-title":"Oridonin inhibits epithelial-mesenchymal transition of human nasopharyngeal carcinoma cells by negatively regulating AKT\/STAT3 signaling pathway","volume":"18","author":"Liu","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.intimp.2026.116423_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661323","article-title":"Tumor NLRP3-derived IL-1beta drives the IL-6\/STAT3 Axis resulting in sustained MDSC-mediated immunosuppression","volume":"12","author":"Tengesdal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116423_bb0235","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/s12276-024-01298-9","article-title":"STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation","volume":"56","author":"Luo","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116423_bb0240","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2147\/OTT.S133385","article-title":"Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies","volume":"10","author":"Ilcus","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.intimp.2026.116423_bb0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:00:05Z","timestamp":1778619605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926002675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S1567576926002675"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116423","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oridonin downregulates PD-L1 expression and promotes anti-tumor immunity via inhibiting NLRP3 and STAT3","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116423"}}